Kirin Holdings Company ((KNBWF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Kirin Holdings Company is collaborating with RDC Clinical Pty Ltd on a clinical study titled ‘A Randomized Controlled Trial Evaluating the Efficacy of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria in Preventing Upper Respiratory Tract Infections and Reducing Symptom Severity and Duration.’ The study aims to assess the effectiveness of LC-Plasma in preventing upper respiratory tract infections (URTIs) among healthy individuals, highlighting its potential significance in public health.
Intervention/Treatment: The study tests LC-Plasma, a dietary supplement, against a placebo. Participants will consume a daily tablet containing 50mg of LC-Plasma or a placebo for 24 weeks, aiming to determine the supplement’s preventive capabilities against URTIs.
Study Design: This Phase 3 interventional study employs a randomized, parallel assignment model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is prevention, focusing on the efficacy of LC-Plasma in reducing URTIs.
Study Timeline: The study began on March 28, 2025, with the primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 22, 2025, indicating ongoing recruitment and progress.
Market Implications: The study’s progress could influence Kirin Holdings’ stock performance, as positive results may enhance investor confidence and market positioning in the dietary supplement industry. Competitors in the health and wellness sector will likely monitor these developments closely, considering potential impacts on market dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.